关于levosimendan的图书统计分析
Xian-Shu Zhao1, Yi-Ping Yu2, Yun-Tai Yao1
1Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
International journal of cardiology. Heart & vasculature
|January 13, 2025
概括
这种对levosimendan (LEVO) 出版物的文献计量分析揭示了越来越多的研究趋势,美国在产出方面处于领先地位. 安全性和有效性成为这项心力衰竭治疗的全球研究热点.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 图书统计学 图书统计学
背景情况:
- 莱沃西门丹 (LEVO) 是一种敏感剂和通道开启剂,用于高级心力衰竭和相关疾病.
- 现有的LEVO出版物缺乏全面的数据,阻碍了新的研究和综合信息检索.
- 图书统计分析对于识别LEVO文献中的研究趋势和知识差距至关重要.
研究的目的:
- 在levosimendan (LEVO) 出版物中识别研究趋势和热点.
- 提供关于LEVO研究当前状况的全面概述.
- 为LEVO.提供对未来研究方向的见解.
主要方法:
- 从1990年到2023年的LEVO相关出版物的系统搜索在科学网络核心集合中进行.
- 使用VOSviewer,CiteSpace,Scimago Graphica,R-bibliometrix和Rstudio.com进行了图书法测量分析.
- 分析的数据包括出版日期,国家,机构,作者,关键词,期刊和参考文献.
主要成果:
- 总共包括了1432篇LEVO文章,显示出版物每年增加.
- 美国是最富有生产力的国家,赫尔辛基大学是主要机构,波莱塞洛教授,皮埃罗是最多产的作家.
- 联合引用和引用突发分析确定了LEVO的安全性和有效性作为全球研究趋势和潜在的热点.
结论:
- 本研究系统地总结了目前的levosimendan (LEVO) 研究格局.
- 它强调了主要的研究重点,包括LEVO的安全性和有效性.
- 这些发现为LEVO的潜在未来研究热点提供了有价值的见解.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.7K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Heart Failure Drugs: β-Blockers
2.6K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.6K
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K


